Pharmaceuticals, Biotechnology and Life Sciences
CAMBRIDGE, England–(BUSINESS WIRE)–Cycle Pharmaceuticals Ltd (Cycle) is pleased to announce that it has signed an agreement with Catalent, Inc. (Catalent)…
Analyses of tebentafusp data provide further insight into platform’s mechanism of action, potential link to clinical activity in uveal melanoma…
Signature of a framework agreement with Institut Pasteur in gene therapy Financial position strengthened with the issuance of a €20m…
FY2019 H1 revenue 1660.2 billion yen, up +88.5% versus prior year mainly due to acquisition of Shire and solid performance…
Exclusive Collaboration Utilizes Pandion’s Platform to Discover Novel Tissue-Specific Immunomodulators for Type 1 Diabetes and Other Autoimmune Diseases of the…
NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICES VANCOUVER, British Columbia–(BUSINESS WIRE)–Sproutly Canada, Inc. (CSE: SPR) (FRA:…
NEWARK, Calif.–(BUSINESS WIRE)–Aradigm Corporation (OTCQB: ARDMQ) (“Aradigm” or the “Company”) today announced that following a recent Oral Explanation, it has…
Biogen and Alkermes got approval from USFDA for Vumertiy, a novel oral fumarate with a distinct chemical structure, for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.
Amgen said in a press release Tuesday it’s total revenues decreased 3% to $5.7 billion compared with the same period last year, reflecting the impact of biosimilar and generic competition against key products.
Q-linea AB has received the official response including a number of clarifications and very positive feedback from the US Food and Drug Administration, FDA, regarding the company’s planned pivotal clinical trial with ASTar in the United States.